|
1
|
miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells.
|
J Biol Chem
|
2011
|
1.98
|
|
2
|
Myeloid sarcomas: a histologic, immunohistochemical, and cytogenetic study.
|
Diagn Pathol
|
2007
|
1.46
|
|
3
|
Increasing national mastectomy rates for the treatment of early stage breast cancer.
|
Ann Surg Oncol
|
2012
|
1.35
|
|
4
|
Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity.
|
Clin Exp Metastasis
|
2008
|
1.25
|
|
5
|
Circulating giant macrophages as a potential biomarker of solid tumors.
|
Proc Natl Acad Sci U S A
|
2014
|
1.18
|
|
6
|
Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.
|
Cancer Res
|
2011
|
1.09
|
|
7
|
Targeting abnormal DNA repair in therapy-resistant breast cancers.
|
Mol Cancer Res
|
2011
|
1.07
|
|
8
|
A Role for OCT4 in Tumor Initiation of Drug-Resistant Prostate Cancer Cells.
|
Genes Cancer
|
2010
|
1.06
|
|
9
|
Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.
|
Cytometry A
|
2014
|
1.02
|
|
10
|
Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms.
|
Cancer
|
2013
|
0.93
|
|
11
|
The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer.
|
Breast Cancer Res Treat
|
2012
|
0.93
|
|
12
|
A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors.
|
Breast Cancer Res Treat
|
2013
|
0.92
|
|
13
|
Nicotine promotes apoptosis resistance of breast cancer cells and enrichment of side population cells with cancer stem cell-like properties via a signaling cascade involving galectin-3, α9 nicotinic acetylcholine receptor and STAT3.
|
Breast Cancer Res Treat
|
2014
|
0.88
|
|
14
|
Profound thrombocytopenia in patient with ITP treated with chemotherapy for breast cancer and subsequent remission after romiplostim.
|
Ann Hematol
|
2013
|
0.80
|
|
15
|
Similar survival with breast conservation therapy or mastectomy in the management of young women with early-stage breast cancer.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.80
|
|
16
|
Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
|
Breast Cancer Res
|
2014
|
0.79
|
|
17
|
Aromatase inhibitors and breast cancer.
|
Horm Mol Biol Clin Investig
|
2012
|
0.79
|
|
18
|
Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma.
|
Leuk Lymphoma
|
2008
|
0.76
|
|
19
|
Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
|
Breast Cancer Res Treat
|
2015
|
0.76
|
|
20
|
Extending aromatase inhibitor sensitivity in hormone resistant breast cancer.
|
Horm Mol Biol Clin Investig
|
2011
|
0.75
|
|
21
|
High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy.
|
Chemotherapy
|
2017
|
0.75
|
|
22
|
Combined cancer therapy: strategies to overcome acquired aromatase inhibitor resistance.
|
Curr Pharm Des
|
2014
|
0.75
|
|
23
|
Persistent positron emission tomography positivity secondary to benign histiocytic proliferation after treatment of Hodgkin lymphoma.
|
Leuk Lymphoma
|
2007
|
0.75
|